In the BioHarmony Drug Report Database
Ubrogepant
Ubrelvy (ubrogepant) is a small molecule pharmaceutical. Ubrogepant was first approved as Ubrelvy on 2019-12-23. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. It is known to target calcitonin gene-related peptide type 1 receptor. Ubrelvy’s patents are valid until 2035-01-30 (FDA).
Trade Name
|
Ubrelvy |
|---|---|
Common Name
|
ubrogepant |
ChEMBL ID
|
CHEMBL2364638 |
Indication
|
migraine disorders, migraine with aura, migraine without aura |
Drug Class
|
Calcitonin gene-related peptide receptor antagonists |
Image (chem structure or protein)